Back to Online Symposia Home Page![]()
|
Learning Objectives
Who Will Benefit
James W. Jefferson, MD, has received grants and/or research support from Bristol-Myers Squibb Company, Forest, GlaxoSmithKline, Janssen, L.P., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon Pharmaceuticals USA, Inc., Pfizer Inc., Roche Laboratories Inc., Solvay Pharmaceuticals, UCB Pharma Inc., and Wyeth Pharmaceuticals Inc. He has also has received honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb Company, Forest, GlaxoSmithKline, Eli Lilly and Company, Pfizer Inc., UCB Pharma Inc., Shire Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has served as a consultant for GlaxoSmithKline, Organon Pharmaceuticals, Shire Pharmaceuticals, and UCB Pharma Inc. He is the principal of Healthcare Technology Systems, Inc., and a stockholder in Bristol-Myers Squibb Company GlaxoSmithKline and SciClone He receives other financial or material support from the organizations listed above from time to time.
|
||||
Commercial
Support
Disclaimers To earn continuing
education credit, view this online course and complete the posttest and
evaluation provided. A passing score of 75% or more
must be achieved on the posttest. A link is provided within this online
activity to access the posttest and evaluation. You will have the option of
printing a CME Certificate for your records after submission of the
evaluation.
CME LLC, Bristol-Myers
Squibb Company and Otsuka America Pharmaceutical,
Inc. are not responsible for the speaker's statements, materials, acts or
omissions.
|
Continuing
Medical Education CME LLC designates this
educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Content Originally
Presented: March 1, 2008
|
||||
Terms of Service Privacy Advertising
|